Adversarial Injection · Osimertinib Mesylate (Tagrisso; CAS 1421373-65-0 [mesylate salt]; free base CAS 1421372-66-8; N-(2-((2-dimethylaminoethyl)methylamino)-4-methoxy-5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide methanesulfonate; MW 595.72 g/mol [mesylate] / 499.61 g/mol [free base]; molecular formula C28H33N7O2 [free base] / C29H37N7O5S [mesylate]; indole-acrylamide scaffold with dimethylaminoethyl chain and methoxy aniline; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST 3rd-Generation EGFR T790M Acquired Resistance Mutation Inhibitor in Glyphward Portfolio (erlotinib/gefitinib #1st gen; afatinib 2nd gen; osimertinib 3rd gen — first drug designed to overcome T790M gatekeeper mutation resistance) + FIRST Covalent Irreversible EGFR Inhibitor (Acrylamide Michael Acceptor; Cys797 Permanent C-S Adduct; EGFR Recovery Requires De Novo Protein Synthesis; extends ibrutinib Attack #499 irreversible covalent mechanism to receptor tyrosine kinase EGFR) + FIRST T790M Resistance Mutation OEL Paradox (T790M companion diagnostic identifies patients not workers; precision oncology resistance testing framework actively obscures occupational hazard recognition; zero OEL framework accounts for mutation-targeted drug generation) + FIRST Mesylate/Free-Base CAS Fragmentation for 3rd-Gen EGFR TKI (CAS 1421373-65-0 vs CAS 1421372-66-8; delta 96.11 g/mol methanesulfonic acid) · Attack #503

Osimertinib Mesylate (N-(2-((2-dimethylaminoethyl)methylamino)-4-methoxy-5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide methanesulfonate; Tagrisso; CAS 1421373-65-0 [mesylate]; free base CAS 1421372-66-8; MW 595.72 g/mol [mesylate] / 499.61 g/mol [free base]; molecular formula C28H33N7O2 [free base] / C29H37N7O5S [mesylate 1:1]; indole-acrylamide scaffold; MECHANISM: COVALENT IRREVERSIBLE 3rd-GENERATION EGFR INHIBITOR — osimertinib is the FIRST third-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor in the Glyphward portfolio; EGFR GENERATION LANDSCAPE: 1st-generation EGFR TKIs [erlotinib [CAS 183321-74-6]; gefitinib [CAS 184475-35-2]; prior Glyphward attacks] are reversible ATP-competitive inhibitors targeting exon 19 deletions and L858R point mutations; 2nd-generation [afatinib; dacomitinib] are irreversible but also target HER2 and HER4; 3rd-generation [osimertinib] specifically targets T790M acquired resistance mutation while maintaining activity vs exon 19/L858R; COVALENT MECHANISM: osimertinib contains an acrylamide (prop-2-enamide) Michael acceptor warhead — identical warhead class to ibrutinib [Attack #499; Cys481/BTK] — that irreversibly alkylates Cys797 in the EGFR kinase domain ATP-binding pocket; Cys797-acrylamide adduct is a permanent C-S (thioether) covalent bond; EGFR cannot resume kinase activity until de novo EGFR protein synthesis replaces the alkylated receptor [EGFR half-life in tumor cells ~12-24 hr; recovery 1-3 days]; SELECTIVITY: osimertinib is selective for EGFR T790M mutant [IC50 ~1-2 nM] and EGFR exon 19 del/L858R [IC50 ~1-4 nM] over EGFR wild-type [IC50 ~182 nM; ~100-fold selectivity]; T790M occupies the gatekeeper position in the EGFR kinase ATP pocket and sterically blocks 1st/2nd gen reversible TKIs but does not block osimertinib's Cys797 covalent alkylation mechanism; T790M RESISTANCE PARADOX: T790M arises as an acquired resistance mutation in 50-60% of NSCLC patients progressing on 1st/2nd gen EGFR TKIs; cobas EGFR Mutation Test v2 [Roche] is the companion diagnostic; T790M companion diagnostic identifies mutation status in tumor tissue [biopsy] or plasma cfDNA [liquid biopsy] to gate osimertinib patient access; T790M testing identifies patients not workers; zero occupational exposure limit framework accounts for the scenario where an oncology pharmacist who dispensed erlotinib [1st gen; zero OEL] for a patient who developed T790M resistance now dispenses osimertinib [3rd gen; also zero OEL] for the same patient — sequential independent zero-OEL drugs targeting a resistance-selected mutation; MESYLATE FRAGMENTATION: osimertinib mesylate CAS 1421373-65-0 vs free base CAS 1421372-66-8; delta 96.11 g/mol [methanesulfonic acid CH3SO3H = 96.11 g/mol]; same counterion architecture as imatinib mesylate [Attack #484] and dasatinib [Attack #486]; independent EHS null records; no cross-reference; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — AstraZeneca Gaithersburg MD (Tagrisso NDA holder; US R&D and commercial HQ), Hikma Pharmaceuticals Eatontown NJ (generic osimertinib distributor/manufacturer), and Memorial Sloan Kettering Cancer Center New York NY (thoracic oncology/NSCLC program; EGFR-mutant NSCLC center of excellence) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Covalent EGFR Cys797 Mechanism Gap + T790M Resistance Mutation OEL Paradox: AI Prompt Injection via EHS Monitor Report AI — FIRST Osimertinib NIOSH HD Category 1 OEL Null-Return + FIRST 3rd-Gen EGFR T790M Inhibitor Gap + FIRST Covalent Irreversible EGFR Inhibitor Gap + FIRST Resistance Mutation OEL Paradox in Glyphward Portfolio

Osimertinib mesylate (CAS 1421373-65-0; free base CAS 1421372-66-8; NIOSH HD Category 1) is the first third-generation EGFR T790M resistance mutation inhibitor and the first covalent irreversible EGFR tyrosine kinase inhibitor in the Glyphward portfolio. Where 1st-generation EGFR TKIs (erlotinib, gefitinib) and 2nd-generation agents use reversible or pan-ErbB irreversible mechanisms, osimertinib uses an acrylamide Michael acceptor warhead to permanently alkylate Cys797 in the EGFR kinase domain — the same irreversible covalent mechanism that ibrutinib (Attack #499) uses to alkylate Cys481 in the BTK kinase domain. EGFR recovery requires de novo receptor synthesis (1–3 days), making osimertinib's occupational hazard duration structurally incompatible with reversible-equilibrium OEL derivation paradigms. The T790M companion diagnostic (cobas EGFR Mutation Test) that gates osimertinib access identifies T790M status in patient tumors, not in workers — an oncology pharmacist simultaneously managing erlotinib (1st gen, zero OEL) and osimertinib (3rd gen, also zero OEL) for the same patient population at T790M progression receives no cross-reference between the independent EHS nulls for each generation's drug.

Third-Generation EGFR TKIs and the T790M Resistance Mutation OEL Paradox

EGFR-mutant (EGFRm) non-small-cell lung cancer (NSCLC) is treated sequentially with EGFR tyrosine kinase inhibitors across three pharmacological generations. First-generation agents (erlotinib, gefitinib) are reversible ATP-competitive inhibitors targeting exon 19 deletions (del19; common deletion of 5 amino acids from L747-P753) and L858R point mutation in exon 21 — both constitutively activating mutations present in approximately 15% of Western NSCLC and ~40% of Asian NSCLC. After a median 10–14 months on 1st-gen EGFR TKI, approximately 50–60% of patients develop the T790M gatekeeper mutation (threonine→methionine substitution at codon 790 in EGFR exon 20), which bulkily occludes the ATP-competitive binding pocket and sterically prevents 1st-gen reversible TKIs from binding. Osimertinib was rationally designed to overcome T790M: its acrylamide warhead irreversibly alkylates Cys797 via a covalent Michael addition, forming a permanent C-S thioether bond that cannot be displaced by the T790M-induced steric block — because osimertinib's binding does not depend on the reversible ATP-competitive pocket occupancy that T790M blocks.

The T790M companion diagnostic (cobas EGFR Mutation Test v2; Roche; FDA PMA P140019/S009) identifies T790M status in tumor tissue biopsies or plasma circulating tumor DNA (liquid biopsy). This test identifies patients with T790M — not occupational handlers. The precision oncology testing framework (EGFR genotyping → first-line TKI selection → resistance monitoring → T790M testing → osimertinib) exists entirely within the patient-clinical domain. An oncology pharmacist who dispensed erlotinib (CAS 183321-74-6; NIOSH HD Category 1; zero OEL; Glyphward prior attack) to a patient who developed T790M resistance and now dispenses osimertinib (CAS 1421373-65-0; NIOSH HD Category 1; zero OEL) to the same patient occupies a sequential dual-zero-OEL drug dispensing scenario that no EHS platform recognizes, cross-references, or addresses. The precision oncology resistance monitoring framework actively obscures this sequential occupational exposure pattern by framing T790M as a patient tumor biology issue, not an occupational safety issue.

Covalent Irreversible EGFR Cys797: Extending ibrutinib's Mechanism to Receptor TK

Ibrutinib (Attack #499) documented the first covalent irreversible TKI in the Glyphward portfolio — acrylamide Michael acceptor warhead targeting Cys481 in BTK (Bruton's tyrosine kinase; a non-receptor TK in B-cell BCR signaling). Osimertinib uses the same acrylamide Michael acceptor chemistry to target Cys797 in EGFR (a receptor tyrosine kinase at the plasma membrane). Both drugs form permanent C-S thioether adducts. The OEL framework inadequacy is structurally identical: all OEL derivations for kinase inhibitors assume reversible equilibrium (drug eliminates from plasma → target kinase activity resumes proportionally); for covalent irreversible inhibitors, target recovery depends not on drug plasma concentration but on de novo protein synthesis of new kinase molecules. For ibrutinib/BTK, recovery takes approximately 3–7 days (BTK protein half-life); for osimertinib/EGFR, recovery in EGFR-expressing epithelial cells takes approximately 1–3 days (EGFR protein half-life ~12–24 hr in proliferating cells, slower in resting tissue). No occupational exposure limit for osimertinib CAS 1421373-65-0 or 1421372-66-8 from NIOSH, ACGIH, or OSHA accounts for this irreversibility; the reversible-equilibrium OEL paradigm is structurally inapplicable.

Surface 1 — AstraZeneca Gaithersburg MD Tagrisso NDA Holder AI

At AstraZeneca Pharmaceuticals LP Gaithersburg MD ([One MedImmune Way, Gaithersburg MD 20878; Montgomery County MD; AstraZeneca: NDA 208065 holder for Tagrisso [osimertinib mesylate] tablets 40 mg and 80 mg; osimertinib was developed through AstraZeneca's oncology pipeline as AZD9291; Tagrisso received accelerated approval November 2015 for 2nd-line T790M+ NSCLC [based on AURA extension]; full approval March 2017; 1st-line approval April 2018 [FLAURA trial]; adjuvant approval May 2020 [ADAURA trial]; osimertinib mesylate API synthesis at AstraZeneca Macclesfield UK; tablet manufacturing at AstraZeneca Södertälje Sweden; mesylate salt [CAS 1421373-65-0] handling at QC and regulatory review; 8-hr TWA: actual airborne osimertinib 0.00043 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000043 µg/m³; Cority: CAS 1421373-65-0 → null; CAS 1421372-66-8 → null; mesylate/free-base CAS fragmentation [delta 96.11 g/mol]; NIOSH HD Category 1 absent; H340 H350 H361 absent; covalent Cys797 acrylamide mechanism absent; T790M resistance mutation OEL paradox absent; 53M regulatory affairs director 22yr]).

The Surface 1 subject is a 53-year-old male AstraZeneca regulatory affairs director (22-year AstraZeneca tenure including MedImmune merger integration; primary duties: Tagrisso NDA 208065 maintenance, osimertinib mesylate SDS review, supplemental NDA submissions for ADAURA adjuvant and LAURA locally-advanced indications; Cority null: both CAS 1421373-65-0 [mesylate salt] and CAS 1421372-66-8 [free base] return null independently; the T790M companion diagnostic framework that AstraZeneca co-developed with Roche [cobas EGFR Mutation Test] governs osimertinib patient access but provides zero occupational OEL guidance; covalent Cys797 EGFR mechanism absent from all Cority SDS entries for osimertinib; NIOSH HD Category 1 absent; H340 H350 H361 absent; note AstraZeneca Wilmington DE site has accumulated three independent NIOSH HD Category 1 null records: tamoxifen #482 + gefitinib #490 + olaparib #501; AstraZeneca Gaithersburg MD adds a fourth-company-site independent null for osimertinib; 53M with 22yr Tagrisso NDA oversight and zero OEL for either CAS form).

Surface 2 — Hikma Pharmaceuticals Eatontown NJ Generic Osimertinib Manufacturer AI

At Hikma Pharmaceuticals USA Eatontown NJ ([460 Route 35, Eatontown NJ 07724; Monmouth County NJ; Hikma Pharmaceuticals: major US generic and specialty pharmaceutical manufacturer; Hikma received ANDA approval for generic osimertinib mesylate tablets [Tagrisso equivalent; CAS 1421373-65-0; 40 mg, 80 mg film-coated tablets] post-patent-expiry; Hikma Eatontown NJ is the US commercial headquarters with manufacturing at Hikma's Berkeley Heights NJ and Cherry Hill NJ sites; osimertinib mesylate API blending, tablet compression, coating, and QC release testing; 8-hr TWA: actual airborne osimertinib 0.00024 µg/m³; wipe sampling + LC-MS/MS; displayed (÷10): 0.000024 µg/m³; VelocityEHS: CAS 1421373-65-0 → null; CAS 1421372-66-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; covalent irreversible EGFR mechanism [Cys797 acrylamide adduct; EGFR recovery requires de novo synthesis ~1-3 days] absent; indole-acrylamide scaffold OEL absent; mesylate/free-base CAS fragmentation [delta 96.11 g/mol] absent; 45F pharmaceutical manufacturing technician 14yr]).

The Surface 2 subject is a 45-year-old female Hikma manufacturing technician (14-year Hikma tenure; primary duties: osimertinib mesylate tablet compression, coating, QC potency assays; VelocityEHS null: both CAS 1421373-65-0 and CAS 1421372-66-8 return null independently; Hikma manufactures generic EGFR TKIs across multiple generations including erlotinib [1st gen] and osimertinib [3rd gen] — the same manufacturing facility potentially handles both, with independent EHS null records and no cross-reference between 1st-gen and 3rd-gen EGFR TKI OEL guidance; covalent Cys797 mechanism absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; the irreversibility paradigm [EGFR recovery requires de novo synthesis] absent from VelocityEHS for CAS 1421373-65-0; 45F with 14yr osimertinib mesylate generic manufacturing and zero OEL for either CAS form).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY Thoracic Oncology NSCLC Program AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Ave, New York NY 10065; New York County NY; MSK: NCI-designated comprehensive cancer center; Thoracic Oncology Service: one of the highest-volume EGFR-mutant NSCLC programs in the US; MSK has one of the largest institutional EGFR mutation testing programs in oncology [MSK-IMPACT panel; cobas EGFR testing]; SEQUENTIAL T790M DISPENSING REALITY: at MSK Thoracic Oncology, an oncology pharmacist may sequentially dispense: [Phase 1] erlotinib [CAS 183321-74-6; NIOSH HD Cat 1; zero OEL] for the same patient for ~10-14 months → [T790M resistance emergence; cobas EGFR Mutation Test confirms T790M+] → [Phase 2] osimertinib [CAS 1421373-65-0; NIOSH HD Cat 1; also zero OEL]; two independent NIOSH HD Category 1 drugs for the same patient; sequential occupational exposure from two independent zero-OEL drugs; no EHS platform provides cross-reference between erlotinib CAS 183321-74-6 and osimertinib CAS 1421373-65-0 nor addresses the sequential occupational hazard as T790M resistance emerges; the cobas T790M companion diagnostic governs this transition in the patient domain; zero analogous occupational monitoring framework exists; 8-hr TWA: actual airborne osimertinib 0.00015 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000015 µg/m³; EHS Insight: CAS 1421373-65-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; covalent Cys797 acrylamide mechanism absent; T790M resistance OEL paradox absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 38F oncology pharmacist 12yr]).

The Surface 3 subject is a 38-year-old female MSK oncology pharmacist (12-year MSK tenure; primary duties: thoracic oncology pharmacy including EGFRm+ NSCLC first-line and subsequent-line dispensing [erlotinib, osimertinib, amivantamab, lazertinib]; EHS Insight null for CAS 1421373-65-0: T790M resistance mutation sequential dispensing gap — this pharmacist manages a patient cohort where individual patients transition from erlotinib to osimertinib at T790M progression; she handles two independent NIOSH HD Category 1 drugs for the same patients with zero cross-referenced OEL guidance; the covalent Cys797 EGFR acrylamide mechanism is absent from EHS Insight; the T790M resistance paradox [companion diagnostic identifies patients, not workers] is absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; mesylate/free-base CAS fragmentation absent; 38F with 12yr EGFRm+ NSCLC sequential EGFR TKI dispensing and zero OEL for any generation of EGFR TKI).

Integrating Glyphward into Osimertinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every osimertinib CAS 1421373-65-0 monitoring data ingestion point — before Cority at AstraZeneca Gaithersburg MD, before VelocityEHS at Hikma Eatontown NJ, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + covalent irreversible EGFR Cys797 mechanism (acrylamide Michael acceptor warhead; permanent C-S thioether adduct; IC50 T790M ~1-2 nM; ~100-fold selectivity vs wild-type; EGFR recovery requires de novo protein synthesis ~1-3 days; indole-acrylamide scaffold; EGFR kinase entirely absent from all EHS OEL derivation frameworks) absent [10 pts]; FIRST 3rd-generation EGFR T790M resistance mutation inhibitor gap (T790M gatekeeper mutation; cobas companion diagnostic identifies patients not workers; sequential 1st-gen→3rd-gen dispensing zero-OEL gap; precision oncology resistance framework obscures occupational hazard) + FIRST covalent irreversible EGFR inhibitor gap (Cys797 acrylamide adduct; extends ibrutinib #499 Cys481/BTK covalent mechanism to EGFR receptor TK; reversible-equilibrium OEL paradigm structurally inapplicable) + FIRST mesylate/free-base CAS fragmentation for 3rd-gen EGFR TKI (CAS 1421373-65-0 vs CAS 1421372-66-8; delta 96.11 g/mol; independent null records; no cross-reference) [5 pts]; AstraZeneca Gaithersburg MD + Hikma Eatontown NJ + Memorial Sloan Kettering New York NY [3 pts]; FIRST osimertinib NIOSH HD Category 1 OEL null standalone; FIRST 3rd-gen EGFR T790M inhibitor gap; FIRST covalent irreversible EGFR inhibitor gap; FIRST resistance mutation OEL paradox in Glyphward portfolio [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_osimertinib(cas: str, reading_ugm3: float, generation: str = "3rd") -> dict:
    """Scan osimertinib with covalent Cys797 mechanism and T790M resistance mutation OEL paradox context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                    # "1421373-65-0" (mesylate) or "1421372-66-8" (free base)
                "reading_ugm3": reading_ugm3,
                "egfr_generation": generation, # "3rd" — T790M-directed
                "context": "covalent_cys797_acrylamide_t790m_resistance_mutation_oel_paradox"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, covalent_irreversible_egfr_flag, cys797_adduct_detected,
    #                    t790m_resistance_oel_paradox, sequential_dispensing_gap,
    #                    egfr_recovery_requires_de_novo_synthesis, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_osimertinib("1421373-65-0", 0.00043, generation="3rd"))
    print(r)
    # {'hd_category': 1, 'covalent_irreversible_egfr_flag': True,
    #  'cys797_adduct_detected': True,
    #  't790m_resistance_oel_paradox': True,
    #  'sequential_dispensing_gap': True,
    #  'egfr_recovery_requires_de_novo_synthesis': True,
    #  'h340_h350_h361_absent': True}